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Abstract
Background: Pulmonary fibrosis (PF) is a group of devastating and largely irreversible diseases. Phosphodiesterase 
(PDE) 4 is involved in the processes of remodeling and inflammation, which play key role in tissue fibrosis. The aim of 
the study was, therefore, to investigate the effect of PDE4 inhibition in experimental model of PF.
Methods: PF was induced in C57BL/6N mice by instillation of bleomycin. Pharmacological inhibition of PDE4 was 
achieved by using cilomilast, a selective PDE4 inhibitor. Changes in either lung inflammation or remodeling were 
evaluated at different stages of experimental PF. Lung inflammation was assessed by bronchoalveolar lavage fluid 
(BALF) differential cell count and reverse transcription quantitative polymerase chain reaction (RT-qPCR) for 
inflammatory cytokines. Changes in tissue remodeling were evaluated by pulmonary compliance measurement, 
quantified pathological examination, measurement of collagen deposition and RT-qPCR for late remodeling markers. 
Survival in all groups was analyzed as well.
Results: PDE4 inhibition significantly reduced the total number of alveolar inflammatory cells in BALF of mice with 
bleomycin-induced PF at early fibrosis stage (days 4 and 7). Number of macrophages and lymphocytes, but not 
neutrophils, was significantly reduced as well. Treatment decreased lung tumor necrosis factor (TNF)-α mRNA level and 
increased mRNA level of interleukin (IL)-6 but did not influence IL-1β. At later stage (days 14 and 24) cilomilast 
improved lung function, which was shown by increase in lung compliance. It also lowered fibrosis degree, as was 
shown by quantified pathological examination of Hematoxilin-Eosin stained lung sections. Cilomilast had no 
significant effect on the expression of late remodeling markers such as transforming growth factor (TGF)-β1 and 
collagen type Ia1 (COL(I)α1). However, it tended to restore the level of lung collagen, assessed by SIRCOL assay and 
Masson's trichrome staining, and to improve the overall survival.
Conclusions: Selective PDE4 inhibition suppresses early inflammatory stage and attenuates the late stage of 
experimental pulmonary fibrosis.
Background
Pulmonary fibrosis represents a group of devastating and
largely irreversible human interstitial lung diseases hav-
ing only limited treatment options. The disease is charac-
terized by chronic interstitial inflammation, abnormal
function of interstitial fibroblasts and deposition of
excessive amounts of collagen, altogether leading to
severe tissue remodeling [1]. Pathological changes are
accompanied by elevated expression of cytokines TNF-α,
IL-1β, IL-6, growth factors and matrix metalloproteases
(MMPs) [2-4]. The most common experimental model of
human PF is bleomycin-induced PF in mice. It is charac-
terized by inflammatory and remodeling stages, which
allows studying different aspects of the disease [5].
Phosphodiesterases are a superfamily of enzymes that
hydrolyze cAMP and/or cGMP and thereby regulate the
intracellular levels of second messengers [6]. Members of
PDE4 family (E.C. 3.1.4.17) are cAMP-specific PDEs
composed of number of isoforms and are highly repre-
sented in the lung [7-10]. As a component of cAMP/pro-
tein kinase A (PKA) pathway PDE4 plays direct role in
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cell proliferation, differentiation and migration through
regulation of the cAMP level [11-13]. Finally, PDE4 repre-
sents the major cAMP-hydrolyzing enzyme in mono-
cytes, lymphocytes and neutrophils and its activation is
required for inflammatory response [8,14,15].
For these reasons, PDE4 inhibitors were suggested for
treatment of several lung diseases as new anti-inflamma-
tory and anti-remodeling agents [16]. Our group has pre-
viously demonstrated that PDE3/4 inhibitor attenuates
migration of pulmonary artery smooth muscle cells
(PASMCs)  in vitro and reverses pulmonary vascular
remodeling  in vivo [17]. PDE4 inhibitor cilomilast was
also shown to suppress the release and activation of
MMP-1 and MMP-9 from lung fibroblasts, which are
known to be involved in PF progression [18]. Further-
more, cilomilast and other PDE4 inhibitors were demon-
strated to inhibit lung TNF-α and TGF-β release, as well
as neutrophil influx in vivo [19-21]. Finally, treatment of
experimental chronic colitis with PDE4 inhibitor rolip-
ram resulted in decreased collagen deposition as well as
TNF-α and TGF-β content in the tissue [22].
In the present study we hypothesized that PDE4 inhibi-
tors are able to modulate both inflammatory response
and tissue remodeling. The aim of the study was, there-
fore, to investigate the effects of selective PDE4 inhibitor
on different aspects of experimental PF in vivo.
Methods
Animals
Adult male 5-6 weeks-old C57BL/6N mice weighting 19-
21 g were obtained from Charles River Laboratories (Ger-
many). Animals were housed under room temperature
and 12/12-hour light/dark cycle with free access to food
and water. All experiments were performed in accor-
dance with the National Institutes of Health Guidelines
on the Use of Laboratory Animals. Both the University
Animal Care Committee and the Federal Authorities for
Animal Research of the Regierungspraesidium Giessen
(Hessen, Germany) approved the study protocol.
Bleomycin administration and treatment groups
At day 0 mice were given anesthesia with isofluran (Bax-
ter, Germany) followed by random orotracheal instilla-
tion of bleomycin (Sigma, Germany) or sterile saline
(0.9% NaCl) with the mouse nose kept pinched. Bleomy-
cin dissolved in sterile saline was given at the dose of 2.8
units/kg. Animals were assigned to the following groups
1) "saline", 2) "bleo+ctrl" and 3) "bleo+cilo". "Saline" group
received instillation of sterile saline at day 0 and was
given vehicle alone (2% aqueous methylcellulose solu-
tion). Mice in "bleo+ctrl" group received instillation of
bleomycin at day 0 and were given vehicle alone. Mice in
"bleo+cilo" group received instillation of bleomycin at day
0 and were treated once a day with 50 mg/kg cilomilast
(SB207499 or Ariflo®, [c-4-cyano-4-(3-cyclopentyloxy-4-
methoxyphenyl)-r-l-cyclohexane carboxylic acid])
(Nycomed, Germany), suspended in vehicle. Solutions
were administered per os via feeding needle, all in the
same manner . T reatment in all groups started at day 0
and lasted till the end of experiment, i.e. for 4, 7, 14 or 24
days.
Bronchoalveolar lavage fluid cell count
At days 4 and 7 after bleomycin instillation mice were
euthanized by injecting a lethal dose of pentobarbital.
Lungs were flushed three times with 0.5 ml ice cold PBS-
EDTA, recovered fluid was centrifuged and cell pellet was
re-suspended in 1 ml of ice-cold saline. T otal cell count
was performed using Neubauer counting chamber (depth
0.1 mm, 0.0025 mm2; Optik Labor, Germany). For differ-
ential cell count cells in constant volume of 0.2 ml of PBS
were transferred to a glass slide with Cytospin-3 centri-
fuge (Shandon Scientific Ltd, UK) and stained with May
Gruenwald/Giemsa. Numbers of macrophages, neutro-
phils and lymphocytes were determined by counting on
light microscope (Q550IW; Leica, Germany) among 100
of total cells. These data were then extrapolated to num-
ber of cells per milliliter.
Lung compliance and histological examination
At days 14 and 24 after bleomycin instillation mice were
subjected to lung compliance measurement as described
previously [23]. Briefly, animals were anesthetized with
i.p. injection of ketamin/xylacinehydrochloride (Bayer,
Germany). Trachea was canulated, mice were placed in
the chamber and connected to the instrument. Volume of
0.3 ml and pressure of 3 kPa were set for calculating com-
pliance as a ratio of volume to pressure (ml/kPa). Lungs of
mice were isolated at the same time points. Four right
lobes were inflated with 4.5% formaldehyde solution at
constant pressure and fixated as described elsewhere.
After dehydration in tissue processor lung lobes were
individually embedded in paraffin, sectioned at 3 μm on
microtome (all instruments from Leica, Germany),
mounted on glass slides and stained either with Hema-
toxilin-Eosin or Masson's trichrome according to stan-
dard protocols. For histological assessment, Hematoxilin-
Eosin-stained slides were scanned with light microscope
(Leica, Germany) at 100× magnification yielding 50-100
images for each lobe (up to 300 per animal). Each of the
images was reviewed and degree of fibrosis was assigned
according to Ashcroft's fibrosis score system [24] with
slight modifications: normal lung was referred to as score
"0" while score "6" represented maximal degree of patho-
logical changes.
Collagen assay
Level of collagen in lung tissues was determined by SIR-
COL collagen assay (Biocolor Ltd., UK) according to
manufacturer's instructions. Briefly, left lung lobes wereUdalov et al. BMC Pulmonary Medicine 2010, 10:26
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homogenized and collagen was solubilized in 0.5 M acetic
acid. Extracts were incubated with Sirius red dye and
absorbance was determined at 540 nm with spectropho-
tometer Infinite M200 (Tecan, Austria). Amount of colla-
gen was expressed in μg/g of wet tissue.
Survival analysis
Survival of mice for each treatment group was expressed
in percent of animals left of original number at the spe-
cific time points of the experiment. Mice were followed
up for 24 days.
RNA isolation and cDNA synthesis
F o r  R N A  e x t r a c t i o n  l e f t  l u n g  l o b e s  w e r e  i s o l a t e d  a n d
snap-frozen in liquid nitrogen. Tissues were homoge-
nized with Precellys 24 homogenizer (Bertin Technolo-
gies, France) in 0.5 ml of TRIzol reagent (Invitrogen,
USA) and RNA was extracted according to standard pro-
tocol. cDNA synthesis was carried out with ImProm-II™
Reverse Transcription System (Promega, USA) according
to manufacturer's instruction.
Real-time polymerase chain reaction
For quantitative real-time PCR analysis, cDNA was
amplified with Platinum® SYBR® Green qPCR SuperMix-
UDG mix (Invitrogen, USA). Specific PCR primers (Met-
abion, Germany), designed to anneal to adjacent exons to
exclude possible amplification from genomic DNA, were:
mouse β-actin 5'-CTCTAGACTTCGAGCAGGAGATG-
3' (forward) and 5'-CACTGTGTTGGCATAGAG-
GTCTT-3' (reverse); mouse TNF-α 5'-GCCTATGTCT-
CAGCCTCTTCTC-3' (forward) and 5'-CACTTGGTG
GTTTGCTACGA-3' (reverse); mouse IL-1β 5'-GAG-




(reverse); mouse COL(I)a1 5'-AGCTTTGTGGACCTC-
CGGCT-3' (forward) and 5'-ACACAGCCGTGCCATT-
GTGG-3' (reverse); mouse TGF-β1 5'-AACCCCCATTG
CTGTCCCGT-3' (forward) and 5'-CCTTGGTTCAGC-
CACTGCCG-3' (reverse). Quantitative real-time PCR
was carried out in Srtratagene Mx3000P™ qPCR system
(Stratagene, USA) and data were analyzed with accompa-
nying software. The instrument was programmed as fol-
lows: denaturation, 95°C for 10 min; 40 cycles with
denaturation at 95°C for 30 s, annealing at 58-60°C for 30
s and extension at 72°C for 30 s. To ensure that specific
single product is generated dissociation curves were eval-
uated. Relative expression levels were calculated as ΔCt
values by normalizing Ct values of target genes to Ct val-
ues of β-actin as previously described [17].
Statistical analysis
All data are presented as means +/- SEM. The differences
among groups were assessed by one-way Analysis of Vari-
ance (ANOVA) test and Student-Newman-Keuls post-
test for multiple comparisons. A p-value less than 0.05
was considered statistically significant.
Results
Effect of PDE4 inhibition on alveolar inflammatory cells 
content
To assess the effect of cilomilast on lung inflammation,
BALF was collected at early stage of bleomycin-induced
fibrosis from healthy mice treated with vehicle and mice
that received bleomycin and treated either with cilomilast
or vehicle. Total number of alveolar inflammatory cells
was dramatically increased by instillation of bleomycin
(Fig. 1). In contrast, number of cells was significantly
lower in groups that received cilomilast, both at 4 and 7
days (p < 0.001 and p < 0.05 respectively).
To further evaluate the action of cilomilast on different
inflammatory cell types differential cell count was per-
formed (Fig. 1). As expected, all cell types were highly
present in alveolar space after bleomycin instillation, with
the highest increase in number of lymphocytes and neu-
trophils. Number of macrophages and lymphocytes was
significantly decreased by cilomilast both at 4 days (p <
0.001 for both cell types) and 7 days (p < 0.05 and p < 0.01
for macrophages and lymphocytes respectively). Number
of neutrophils, however, remained unchanged.
Effect of PDE4 inhibition on lung inflammatory markers
To evaluate the expression of major inflammatory mark-
ers after cilomilast treatment, lung homogenate RT-
q P C R  w a s  c a r r i e d  o u t  a t  t h e  s a m e  t i m e  p o i n t s  a s  f o r
BALF cell count. At 4 and 7 days after bleomycin instilla-
tion lung expression of TNF-α, IL-1β and IL-6 was signif-
icantly elevated compared to animals that received saline
(Fig. 2). Treatment with cilomilast significantly lowered
TNF-α mRNA level (p < 0.001 at 4 and 7 days) and
increased IL-6 mRNA level (p < 0.05 at 4 and 7 days)
compared to mice treated with vehicle. No significant
change, however, was observed in the level of IL-1β.
Effect of PDE4 inhibition on lung function and pathology
To examine the effect of cilomilast on tissue remodeling
at late stage fibrosis, lung compliance and pathological
changes were evaluated in animals treated either with cil-
omilast or vehicle, as well as in mice received instillation
of saline and treated with vehicle. Pulmonary compliance
(Fig. 3) was significantly lower in mice with bleomycin-
induced fibrosis both at 14 and 24 days, which shows a
typical decrease in elasticity of the lung tissue. Treatment
with cilomilast partially restored impaired lung function
with improvement being significant at 14 days (p < 0.05),
compared to mice treated with vehicle alone.
Similarly, pathological changes estimated by means of
microscopy followed by scoring (Fig. 3) evidenced signifi-
cant distortion of lung architecture in mice with bleomy-Udalov et al. BMC Pulmonary Medicine 2010, 10:26
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cin-induced fibrosis. Degree of fibrosis was lower in lungs
of animals treated with PDE4 inhibitor compared to ones
treated with vehicle only, reaching significance at day 24
(p < 0.05).
Representative images of lung sections stained with
Hematoxilin-Eosin (Fig. 4) demonstrate the degree of
mentioned pathological changes quantified by fibrosis
scoring.
Effect of PDE4 inhibition on lung collagen content and 
remodeling markers
Collagen content in the lungs was estimated by SIRCOL
assay, Masson's trichrome staining and RT-qPCR for
COL(I)α1 at day 24 or at day 14 and 24 after bleomycin
administration in all treatment groups. Total collagen
assay (μg/g tissue) showed significant 2-fold increase
among mice received bleomycin (Fig. 5), which was con-
firmed by Masson's trichrome staining (Additional file 1).
Treatment with cilomilast tended to reduce collagen con-
tent in the lungs, although the effect was rather moder-
ate. In contrast, virtually no effects were observed at
mRNA level of COL(I)α1 at particularly at day 24 (Addi-
tional file 2). Similarly to collagen, cilomilast had no sig-
nificant effect on mRNA level of TGF-β1 (Additional file
3).
Effect of PDE4 inhibition on survival
General effect of cilomilast on the course of experimental
PF was evaluated by survival analysis (Fig. 6). Inhibition
of PDE4 had beneficial effect on survival as was seen at
the end of experiment (day 24) in the group that received
cilomilast compared to one treated with vehicle alone. No
mortalities were observed in the group that received ster-
ile saline.
Discussion
In the present study we have demonstrated beneficial
anti-inflammatory effects of selective PDE4 inhibitor cil-
omilast at inflammatory stage of experimental PF, includ-
ing reduction in BALF cell numbers, suppression of TNF-
α and stimulation of IL-6 expression. We have also dem-
onstrated improvements in lung function and pathologi-
cal changes at later fibrosis stages. Finally, we have
showed that treatment with PDE4 inhibitor tends to
reduce lung collagen content and to improve the overall
survival of the animals with bleomycin-induced PF.
Both human PF and bleomycin-induced PF in mice are
characterized by chronic interstitial inflammation [1,5].
Given that PDE4 is the major cAMP-hydrolyzing enzyme
in inflammatory cells and that it is necessary for develop-
ing of inflammatory response [8,14,15,25], several studies
Figure 1 PDE4 inhibition suppresses alveolar inflammation at early stage fibrosis. Total cell number, number of macrophages, lymphocytes 
and neutrophils in bronchoalveolar lavage fluid (BALF) of healthy controls treated with vehicle ("saline") and in mice suffering from fibrosis and treated 
either with vehicle ("bleo+ctrl") or cilomilast ("bleo+cilo") at days 4 and 7 after bleomycin instillation. Values are presented as means ± SEM, n = 6. * 
saline vs. bleo+ctrl (*p < 0.05, ***p < 0.001), † bleo+ctrl vs. bleo+cilo († p < 0.05, †† p < 0.01, ††† p < 0.001), # saline vs. bleo+cilo (# p < 0.05, ## p < 0.01).Udalov et al. BMC Pulmonary Medicine 2010, 10:26
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showed beneficial effect of PDE4 inhibitors on such
inflammatory diseases as asthma and chronic obstructive
pulmonary disease (COPD) [16]. Thus, we suggested pos-
itive effect of PDE4 inhibition on inflammatory compo-
nent of PF.
Indeed, cilomilast was the most potent at early stage
(days 4 and 7) of bleomycin-induced PF, when inflamma-
tion is the major characteristic of the pathological process
[5]. Total number of alveolar inflammatory cells in BALF
of treated mice was significantly reduced, as well as num-
ber of macrophages and lymphocytes. These results are
consistent with the fact that PDE4 expression is induced
by inflammatory stimulus and that it mediates activation
and proliferation of T-cells and function of macrophages
[25-28]. In turn, macrophages represent the major
inflammatory cell type in alveolus, thereby strongly influ-
encing total cell count values [29,30].
Neutrophils also play important role in pathological tis-
sue remodeling damaging the lung parenchyma by prote-
olytic enzymes. Indeed, IPF patients have higher numbers
of neutrophils and higher concentrations of granule
enzymes, such as neutrophil elastase, myeloperoxydase,
collagenase and lactoferrin in BALF, plasma and lung tis-
sue [30,31]. Ariga et al. described direct involvement of
PDE4 into neutrophil recruitment and chemotaxis [32]
and Corbel et al. showed a decrease in neutrophils release
by selective PDE4 inhibitor piclamilast in a murine model
of LPS-induced acute lung inflammation [21]. However,
we could not observe the significant suppression of neu-
trophil influx by cilomilast in our experimental setup.
This inconsistency can be explained by early (hours)
t i m e - p o i n t s  u s e d  i n  a c u t e  l u n g  i n f l a m m a t i o n  e x p e r i -
ments. The time-points used in the present work (4 and 7
days) were chosen to more closely mimic the inflamma-
tory component of PF. But at the same time they are
known to correspond to the peak in the neutrophil influx,
therefore making it more difficult to achieve the signifi-
cant improvement [33]. Another explanation might be
the differential ability of the compounds to affect particu-
lar cell types and release of mediators. For instance, one
study showed differential effect of several PDE4 inhibi-
tors on neutrophils and TNF-a release, indeed revealing
some limitations of cilomilast [20].
To find if general suppression of inflammatory cells
release was also reflected in lung inflammatory cytokines
expression, expression of TNF-α, IL-1β and IL-6 was ana-
lyzed at the same time points as the cell count experi-
ments were done. These markers are upregulated in the
lungs of both humans and mice with PF and are the
canonical cytokines expressed at first days 4-7 of experi-
mental PF [2-5]. We demonstrated significantly lower
TNF-α expression in the lungs of mice treated with cilo-
milast compared to those received placebo. Taking into
account lower numbers of BALF macrophages after cilo-
milast treatment it was expected to see downregulation
of TNF-α as macrophages represent one of the major
sources of this cytokine [2]. Similar effects of cilomilast
were also shown by other authors [19]. In addition, signif-
icantly higher expression of IL-6 was observed in cilomi-
last-treated animals, compared to controls. This cytokine
is known to exert anti-inflammatory effects and its exog-
enous administration was shown to decrease BALF cell
recruitment, macrophage-mediated TNF-a production
and lung hydroxyproline content in experimental pneu-
monitis in mice [34]. We suggest, therefore, that increase
in IL-6 expression caused by cilomilast accompanies the
Figure 2 Effect of PDE4 inhibition on lung inflammatory markers 
at early stage fibrosis. TNF-α, IL-6 and IL-1β mRNA levels in healthy 
controls treated with vehicle ("saline") and in mice suffering from fibro-
sis and treated either with vehicle ("bleo+ctrl") or cilomilast ("bleo+ci-
lo") at days 4 and 7 after bleomycin administration. RT-qPCR data are 
normalized to β-actin expression and presented as ΔCt values ± SEM, 
n = 6. * saline vs. bleo+ctrl (***p < 0.001), † bleo+ctrl vs. bleo+cilo († p 
< 0.05, ††† p < 0.001), # saline vs. bleo+cilo (# p < 0.05, ### p < 0.001).Udalov et al. BMC Pulmonary Medicine 2010, 10:26
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general suppression of inflammatory cell influx and TNF-
α content in the lung. Interestingly, cilomilast did not
change lung expression of IL-1β. However, it was previ-
o u s l y  r e p o r t e d  t h a t  P D E 4  i n h i b i t o r s  h a v e  l i t t l e  o r  n o
effect on production of this cytokine [35]. Taken together,
we suggest that PDE4 inhibition suppresses lung inflam-
mation via modulation of TNF-α and IL-6.
Besides inflammation, PF is characterized by tissue
remodeling and accumulation of extracellular matrix
components. This ultimately results in impairment of gas
exchange due to thickened interstitium and in worsening
of lung mechanical properties due to increasing stiffness
of the tissue [1]. As expected, decreased pulmonary com-
pliance, higher fibrosis degree and higher lung collagen
level were observed at days 14 and 24 in mice that
received instillation of bleomycin. Progression of fibrosis
is illustrated by lower compliance and higher fibrosis
score at day 24 compared to day 14. Typical manifesta-
tions of bleomycin-induced PF, such as patchy pattern
and interstitial inflammation were also observed. In turn,
Figure 3 PDE4 inhibition improves lung function and attenuates tissue remodeling at late stage fibrosis. Lung compliance and fibrosis scores 
in healthy controls treated with vehicle ("saline") and in mice suffering from fibrosis and treated either with vehicle ("bleo+ctrl") or cilomilast ("bleo+ci-
lo") at days 14 and 24 after bleomycin administration. Values are presented as means ± SEM, n = 9. * saline vs. bleo+ctrl (***p < 0.001), † bleo+ctrl vs. 
bleo+cilo († p < 0.05), # saline vs. bleo+cilo (### p < 0.001).
Figure 4 PDE4 inhibition attenuates tissue remodeling at late stage fibrosis. Representative images of lungs of healthy controls treated with 
vehicle (a, d) and of mice suffering from fibrosis and treated either with vehicle (b, e) or cilomilast (c, f) at days 14 (a, b, c) and 24 (d, e, f) after bleomycin 
administration. Hematoxilin-Eosin staining, magnification ×100.Udalov et al. BMC Pulmonary Medicine 2010, 10:26
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animals that received cilomilast demonstrated higher
lung compliance and lower fibrosis score. As the infiltra-
tion of inflammatory cells into the interstitium might also
contribute to impairment of the lung function we believe
that the significant improvement in compliance at day 14
results from more effective suppression of interstitial
inflammation at this time point compared to late remod-
eling stage at day 24. Treatment with PDE4 inhibitor also
tended to reduce lung collagen accumulation, as was
shown by total collagen assay and Masson's trichrome
staining, particularly at day 14 after bleomycin adminis-
tration. In contrast, no significant effects were seen at
mRNA level of COL(I)α1, which might result from con-
tribution of other collagen types' expression. Similarly, no
effect of cilomilast treatment on TGF-β1 expression was
observed.
Based on our observations and the results of other
authors we suppose that inhibition of PDE4 affects both
general aspects of PF, namely inflammation and tissue
remodeling itself. At first, PDE4 inhibition suppresses tis-
sue fibrosis by partial elimination of pro-fibrotic environ-
ment, for instance by suppression of inflammatory cells
infiltration, downregulation of TNF-α and stimulation of
IL-6 expression shown in the present work. TNF-α
secreted by macrophages [2,36] is a direct mitogen for
lung fibroblasts [37] and its inhibition can be alone suffi-
cient to attenuate PF [38]. Moreover, it was shown that
PDE4 itself is necessary for TNF-α production and devel-
opment of inflammatory response [15,25]. Secondly,
there are evidences implying that PDE4 inhibitors are
also able to act through inflammation-independent way.
For instance, it was repetitively shown that elevation of
cAMP level results in inhibition of lung fibroblast prolif-
eration, migration, transition to myofibroblasts and colla-
gen production [11-13]. It was also shown that PKA can
directly inhibit Raf thereby affecting the RAS/RAF/MEK/
ERK pathway. Details of this interaction are not fully
understood, however at least three possible mechanisms
are suggested [39]. Our group has also previously demon-
stra t ed tha t cAMP raised by PDE3/4 inhibit or t olafen-
trine inhibits enhanced migration of PASMCs derived
from vessels of rats suffering from pulmonary hyperten-
sion [17]. All together these data suggest that the effects
observed in present study might be accounted to several
independent actions of the PDE4 inhibitor, affecting both
inflammatory process and the effector cells at the site of
ongoing fibrosis.
Conclusions
PDE4 inhibition by cilomilast attenuates bleomycin-
induced pulmonary fibrosis in mice. Primarily, cilomilast
exerts its beneficial effects via reduction of inflammatory
response, although it does not significantly affect neutro-
phils release. Cilomilast treatment also moderately affects
tissue remodeling at late fibrosis stage. This seems to be
the consequence of its anti-inflammatory action,
although direct effect on tissue remodeling via inflamma-
tion-independent mechanism is highly possible.
Additional material
Additional file 1 Effect of PDE4 inhibition on lung collagen deposi-
tion at late stage fibrosis. Representative images of lungs of healthy con-
trols (a, d) and of mice suffering from fibrosis and treated either with vehicle 
(b, e) or cilomilast (c, f) at days 14 (a, b, c) and 24 (d, e, f) after bleomycin 
administration. Masson's trichrome staining, magnification ×100.
Additional file 2 Effect of PDE4 inhibition on lung collagen expres-
sion at late stage fibrosis. mRNA levels of COL(I)α1 in healthy controls 
("saline") and in mice suffering from fibrosis and treated either with vehicle 
("bleo+ctrl") or cilomilast ("bleo+cilo") at days 14 and 24 after bleomycin 
administration. RT-qPCR data are normalized to β-actin expression and pre-
sented as ΔCt values ± SEM, n = 4.
Figure 5 Effect of PDE4 inhibition on lung collagen content at 
late stage fibrosis. SIRCOL assay for the lungs of healthy controls 
treated with vehicle ("saline") and in mice suffering from fibrosis and 
treated either with vehicle ("bleo+ctrl") or cilomilast ("bleo+cilo") at 
day 24 after bleomycin administration. Values are presented as means 
± SEM, n = 4. * saline vs. bleo+ctrl (***p < 0.001), # saline vs. bleo+cilo 
(### p < 0.001).
Figure 6 Effect of PDE4 inhibition on survival. Healthy controls 
treated with vehicle ("saline") and mice suffering from fibrosis and 
treated either with vehicle ("bleo+ctrl") or cilomilast ("bleo+cilo") fol-
lowed up for 24 days after bleomycin instillation. Kaplan-Meier curves, 
n = 9.Udalov et al. BMC Pulmonary Medicine 2010, 10:26
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